Jun-09 -

Melanoma Group

EORTC 18991 – Adjuvant PegIntron treatment in stage III melanoma versus observation after regional lymph node dissection.

A Multicenter Randomized Phase III trial.

EORTC study comparing two treatment regimens for patients with stage III melanoma, found that additional immunotherapy (IFN alpha 2-b) impaired their health-related quality of life (HRQOL) scores. This study helped highlight that adjuvant immunotherapy may not be the most appropriate treatment for high-risk melanoma patients.


Go to Top